To evaluate the real world clinical outcomes of intravitreal ocriplasmin in patients with vitreomacular traction (VMT) with and without full thickness macular holes (FTMH) treated according to NICE guidance.
Alcon,a division of Novartis, has announced that the European Commission has approved Jetrea (intravitreal injection ocriplasmin) in the EU for...
ThromboGenics NV a biotechnology company developing novel treatments for retinal disorders, with a focus on diabetic eye disease, announced that...
Novartis has announced the New England Journal of Medicine (NEJM) published the results of two Phase III studies, Studies 006...
NICE (The National Institute for Health and Care Excellence) has given an initial recommendation to Jetrea (ocriplasmin) from Alcon/Thrombogenics,as an...
JETREA is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns (see section 5.1).
Alcon, the eye care division of Novartis, announces the positive opinion from the Committee for Medicinal Products for Human Use...
Thrombogenics has submitted a biologics license application (BLA) to the FDA for ocriplasmin intravitreal injection 2.5mg/mL as a treatment for...
ThromboGenics has announced that the results from its 2 Year OASIS Phase IIIb study with Jetrea (ocriplasmin) in patients with...
Alcon,a division of Novartis, has announced that it has gained exclusive rights from ThromboGenics, to commercialize ocriplasmin outside the United...